Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · May 11, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking for effective treatments for Gulf War Illness (GWI) by testing three natural substances: curcumin, resveratrol, and stinging nettle. The trial is designed to be flexible, allowing participants to join from anywhere in the United States, making it easier for people from different backgrounds to take part. To be eligible, participants need to meet specific criteria related to GWI and be able to commit to the study for 10 months. However, individuals who are currently pregnant, have certain liver or kidney issues, or are taking certain blood-thinning medications cannot participate.
If you decide to take part in this study, you can expect to contribute to important research aimed at helping others with GWI. The study is currently recruiting participants of all ages, and it will be a great opportunity to potentially benefit from new treatments while helping researchers learn more about this condition. Your involvement could make a real difference in understanding and treating Gulf War Illness.
Gender
ALL
Eligibility criteria
- • In accordance with the Institute of Medicine (IOM) 2014 guidance, participants must meet both the Kansas and CDC (Centers for Disease Control and Prevention) Case Definitions of GWI. Participants must have been deployed to the Persian Gulf Region during the 1990-1991 Gulf War, meet symptom domain criteria, and not have exclusionary medical conditions. The case definitions will be used for inclusionary screening purposes.
- Inclusion Criteria:
- • Meets Kansas GWI Case Definition
- • Meets CDC GWI Case Definition
- • Able to commit to a 10-month study
- Exclusion Criteria:
- • Currently involved in an experimental treatment study
- • Abnormal liver function values
- • Abnormal kidney function values
- • Currently pregnant
- • Blood clotting disorder (contraindicated with all three botanicals)
- • Reported diagnosis of diabetes with an A1C greater than 9
- * The use of contraindicated medications (see below):
- • Anticoagulant medications (such as warfarin, heparin, etc.)
- • Lithium
- • Tacrolimus (Prograf)
- • Cancer medications (Alkylating agents, antitumor antibiotics, Topoisomerase I inhibitors, Tamoxifen)
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Trial Officials
Jarred Younger, PhD
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials